Avaxim 160 U

Avaxim 160 U

vaccine, hepatitis a


Sanofi Pasteur


Zuellig Pharma
Concise Prescribing Info
HAV inactivated
Protection against infection caused by HAV in people ≥16 yr.
Dosage/Direction for Use
0.5 mL dose via IM inj. Administer booster dose between 6 & 12 mth after the 1st dose, & may be administered up to 36 mth after 1st dose.
Hypersensitivity to HAV inactivated vaccine or neomycin. Disease w/ high temp.
Special Precautions
Do not inj SC/IV. Patients w/ weakened immune system due to corticosteroids, cytotoxic drugs, radiotherapy, or other treatments; HIV infection or any other immunocompromising diseases. Haemophilia or prone to bruising or bleeding. Fainting may occur. Not used against other viruses known to infect the liver (hepatitis B, C or E viruses). Liver disease. Pregnancy & lactation.
Adverse Reactions
Mild inj site pain; fatigue. Headache; nausea, vomiting; loss of appetite; diarrhoea, abdominal pain; muscle & joint pain; mild fever.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BC02 - hepatitis A, inactivated, whole virus ; Belongs to the class of hepatitis viral vaccines.
Avaxim 160 U vaccine 160 U/0.5 mL
(pre-filled syringe (w/ or w/o needle) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in